373 related articles for article (PubMed ID: 31845438)
1. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
4. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
7. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
9. Combined high-grade neuroendocrine carcinoma of the lung: clinicopathological and immunohistochemical study of 34 surgically resected cases.
Yamada K; Maeshima AM; Tsuta K; Tsuda H
Pathol Int; 2014 Jan; 64(1):28-33. PubMed ID: 24471967
[TBL] [Abstract][Full Text] [Related]
10. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
14. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
15. Identification of key modules and hub genes for small-cell lung carcinoma and large-cell neuroendocrine lung carcinoma by weighted gene co-expression network analysis of clinical tissue-proteomes.
Nakamura H; Fujii K; Gupta V; Hata H; Koizumu H; Hoshikawa M; Naruki S; Miyata Y; Takahashi I; Miyazawa T; Sakai H; Tsumoto K; Takagi M; Saji H; Nishimura T
PLoS One; 2019; 14(6):e0217105. PubMed ID: 31166966
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous computed tomography-guided core needle biopsy can be used to histologically confirm the clinical features and long-term prognosis of pulmonary neuroendocrine neoplasms.
Chen C; Wang Y; Huang H; He X; Li W
Jpn J Radiol; 2023 Dec; 41(12):1414-1419. PubMed ID: 37395983
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin C-terminal hydrolase L1 promotes lymph node metastasis in small cell neuroendocrine carcinomas of the cervix.
Zhang Y; Ding J; Zhang X; Hua K
J Int Med Res; 2022 Apr; 50(4):3000605221087620. PubMed ID: 35400238
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
19. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
[No Abstract] [Full Text] [Related]
20. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
Recuero E; Lázaro S; Lorz C; Enguita AB; Garcia-Escudero R; Santos M
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]